Diagnosis and Management of Common Opportunistic Infections in People With HIV

Assessment of Needs

Modern antiretroviral therapy has led to a dramatic reduction in HIV-associated opportunistic infections and mortality, but late diagnosis of HIV and poor linkage to care persist and lead to a worse prognosis. HIV care is now focused on early therapy initiation and virologic control, and new practitioners may have less experience and fewer educational resources for the diagnosis and management of opportunistic infections. This webinar will outline the clinical presentation, diagnosis, and management of the most common opportunistic infections in the modern antiretroviral therapy era and present clinical photography, radiographic findings, and microbiologic, endoscopic, pathologic, and retinal images.

Learning Objectives

On completion of this activity, learners will be able to:

• Identify some of the common HIV-associated opportunistic infections based on characteristic clinical findings and diagnostic data, including imaging, microbiologic, pathologic, and other features
• Apply evidence-based approaches to the diagnosis and management of common opportunistic infections in people with HIV
• Describe evidence-based approaches to the diagnosis and management of common opportunistic infections and their complications, such as immune reconstitution inflammatory syndrome (IRIS), in people with HIV

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, November 3, 2026, 11:30 AM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Sereti reported no relevant financial relationships with ineligible companies. (Updated February 6, 2026)

Moderator

Dr Currier reported serving on a data and safety monitoring board for Merck & Co, Inc. (Updated May 12, 2026)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies (Updated February 6, 2026)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies (Updated February 6, 2026)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/